Whipplewood Advisors LLC Sells 84 Shares of Natera, Inc. $NTRA

Whipplewood Advisors LLC lessened its holdings in Natera, Inc. (NASDAQ:NTRA) by 11.2% in the second quarter, Holdings Channel reports. The institutional investor owned 669 shares of the medical research company’s stock after selling 84 shares during the period. Whipplewood Advisors LLC’s holdings in Natera were worth $113,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. HighPoint Advisor Group LLC raised its holdings in Natera by 30.8% in the 1st quarter. HighPoint Advisor Group LLC now owns 1,986 shares of the medical research company’s stock valued at $308,000 after buying an additional 468 shares during the last quarter. Park Avenue Securities LLC bought a new position in Natera during the 2nd quarter worth approximately $1,525,000. Amalgamated Bank raised its holdings in Natera by 9.8% during the 1st quarter. Amalgamated Bank now owns 8,293 shares of the medical research company’s stock worth $1,173,000 after purchasing an additional 740 shares during the last quarter. Comerica Bank raised its holdings in Natera by 24.1% during the 1st quarter. Comerica Bank now owns 141,106 shares of the medical research company’s stock worth $19,954,000 after purchasing an additional 27,379 shares during the last quarter. Finally, GAMMA Investing LLC raised its holdings in Natera by 32.3% during the 1st quarter. GAMMA Investing LLC now owns 848 shares of the medical research company’s stock worth $120,000 after purchasing an additional 207 shares during the last quarter. Institutional investors own 99.90% of the company’s stock.

Insider Buying and Selling at Natera

In related news, CFO Michael Burkes Brophy sold 755 shares of Natera stock in a transaction on Friday, October 24th. The shares were sold at an average price of $196.77, for a total value of $148,561.35. Following the completion of the sale, the chief financial officer owned 69,189 shares of the company’s stock, valued at approximately $13,614,319.53. This trade represents a 1.08% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider John Fesko sold 339 shares of Natera stock in a transaction on Tuesday, October 21st. The shares were sold at an average price of $187.95, for a total transaction of $63,715.05. Following the completion of the sale, the insider directly owned 152,408 shares of the company’s stock, valued at approximately $28,645,083.60. The trade was a 0.22% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 60,419 shares of company stock worth $9,526,405. 5.63% of the stock is owned by company insiders.

Natera Stock Down 1.3%

Shares of NTRA stock opened at $192.51 on Monday. The company has a market cap of $26.42 billion, a price-to-earnings ratio of -100.79 and a beta of 1.74. Natera, Inc. has a 52 week low of $117.27 and a 52 week high of $198.99. The firm has a 50 day moving average of $171.29 and a 200-day moving average of $160.43.

Natera (NASDAQ:NTRA) last announced its quarterly earnings data on Thursday, August 7th. The medical research company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.14). The company had revenue of $546.60 million for the quarter, compared to analyst estimates of $476.84 million. Natera had a negative return on equity of 22.22% and a negative net margin of 12.89%.The business’s quarterly revenue was up 32.2% compared to the same quarter last year. During the same period last year, the business earned ($0.30) EPS. Natera has set its FY 2025 guidance at EPS. Analysts anticipate that Natera, Inc. will post -1.49 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research analysts have issued reports on the stock. Evercore ISI upgraded shares of Natera to a “strong-buy” rating and set a $170.00 price target for the company in a report on Monday, July 28th. Canaccord Genuity Group restated a “buy” rating and set a $200.00 price target on shares of Natera in a report on Tuesday, October 14th. Zacks Research lowered shares of Natera from a “hold” rating to a “strong sell” rating in a report on Monday, October 20th. Piper Sandler restated an “overweight” rating and set a $220.00 price target (up previously from $210.00) on shares of Natera in a report on Monday, August 11th. Finally, Morgan Stanley restated an “overweight” rating and set a $195.00 price target on shares of Natera in a report on Sunday, August 10th. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $197.59.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.